During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
More top news
A remarkably mild night with misty low cloud on the hills of Scotland, Wales and north-west England and further rain in places.
The former head of the Diplomatic Service breaks down the hidden meanings behind Theresa May's letter to Donald Tusk
The storms that struck Texas and Oklahoma late on Tuesday brought tornadoes, tennis ball-sized hail and powerful winds.